August 12, 2015

Biogazelle receives €1.1M IWT funding to develop lncRNA targeting cancer therapies

Biogazelle today announced that it has received €1.1M in funding from the agency for Innovation by Science and Technology (IWT) in Flanders to leverage its cancer therapy development program, focused on silencing long non-coding RNAs (lncRNAs). Last year, Biogazelle initiated the development of lncRNA-targeting therapies in colon, liver and lung cancer.

June 12, 2015

Biogazelle offers unique microRNA sequencing on challenging samples

Biogazelle has a longstanding track record and internationally recognized expertise in RNA gene expression analysis, with a particular focus on non-coding RNA, such as microRNAs and long non-coding RNAs. Today, the service portfolio is extended with a unique offering, namely the use of massively parallel sequencing to quantify microRNAs in compromised samples characterized by degraded RNA or low output amounts of RNA.

February 6, 2015

Biogazelle strengthens its board of directors

On October 6, 2014, Biogazelle announced the closure of an investment round with QBIC Arkiv Fund, Foundation Majoie and SOFI to finance its growth (press release available on Today, Biogazelle announces that it has strengthened its board with two directors representing the new investors and also announces its intention to propose the nomination of Nick McCooke and Jim Van heusden as non-executive directors to the next shareholder meeting.

January 27, 2015

Biogazelle has established a quality management system and is ISO 17025 accredited for gene expression services

Biogazelle is a Ghent University spin-off company founded in 2007 by prof. Jo Vandesompele and dr. Jan Hellemans. With a proven track record in gene expression studies, Biogazelle is at the forefront of transcriptome analyses using state-of-the-art laboratory methods, including RNA sequencing and RT-qPCR.